Connect your AI

Ocular Therapeutix OCUL Contract Liabilities

Contract Liabilities at other companies

Envista Holdings CorporationNVST

$24.1M+21.1%

Henry ScheinHSIC

$9M+28.6%

Other financials

Income statement

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ocular Therapeutix's contract liabilities?: Ocular Therapeutix (OCUL) reported contract liabilities of $14M in Q1 2026.
How has Ocular Therapeutix's contract liabilities changed year-over-year?: Ocular Therapeutix's contract liabilities decreased by 0.0% year-over-year, from $14M to $14M.
What is the long-term trend for Ocular Therapeutix's contract liabilities?: Over 5 years (2020 to 2025), Ocular Therapeutix's contract liabilities has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.
What does contract liabilities mean?: Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.